Immix Biopharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IMMX Nasdaq 2834 www.immixbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immix Biopharma, Inc.

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet - Jun 18th, 2026 7:55 am
Exploring 3 High Growth Tech Stocks in the US Market - Jun 9th, 2026 5:38 am
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - May 27th, 2026 7:55 am
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - May 22nd, 2026 3:15 pm
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - May 21st, 2026 4:30 am
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - May 21st, 2026 4:00 am
3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63% - May 13th, 2026 5:35 am
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? - May 5th, 2026 11:05 am
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth - May 5th, 2026 6:52 am
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Apr 9th, 2026 6:45 am
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - Mar 30th, 2026 6:45 am
Immix Biopharma to Participate in Upcoming Investor Conferences - Mar 3rd, 2026 6:45 am
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Feb 13th, 2026 5:10 am
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - Jan 28th, 2026 6:45 am
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Dec 9th, 2025 3:45 pm
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Dec 7th, 2025 4:20 pm
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Dec 7th, 2025 4:15 pm
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully - Nov 24th, 2025 4:21 am
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - Nov 12th, 2025 6:45 am
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Nov 3rd, 2025 6:45 am